WINTON GROUP Ltd Invests $739,000 in Xeris Biopharma Holdings, Inc. $XERS

WINTON GROUP Ltd purchased a new stake in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) during the 3rd quarter, HoldingsChannel.com reports. The fund purchased 90,793 shares of the company’s stock, valued at approximately $739,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. AlphaQuest LLC purchased a new stake in Xeris Biopharma in the third quarter worth about $35,000. State of Alaska Department of Revenue bought a new stake in shares of Xeris Biopharma in the 3rd quarter valued at about $68,000. R Squared Ltd purchased a new stake in shares of Xeris Biopharma in the 3rd quarter worth approximately $103,000. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Xeris Biopharma in the 3rd quarter worth approximately $107,000. Finally, Vanguard Personalized Indexing Management LLC bought a new position in shares of Xeris Biopharma during the third quarter valued at approximately $127,000. 42.75% of the stock is currently owned by institutional investors.

Xeris Biopharma Stock Up 0.8%

NASDAQ XERS traded up $0.05 during trading on Friday, hitting $5.53. The company’s stock had a trading volume of 285,561 shares, compared to its average volume of 2,048,657. Xeris Biopharma Holdings, Inc. has a fifty-two week low of $3.81 and a fifty-two week high of $10.08. The company has a market cap of $952.68 million, a PE ratio of -553.05 and a beta of 0.61. The company has a debt-to-equity ratio of 16.10, a current ratio of 2.19 and a quick ratio of 1.57. The business’s 50 day simple moving average is $6.94 and its 200-day simple moving average is $7.53.

Xeris Biopharma (NASDAQ:XERS) last posted its quarterly earnings data on Monday, March 2nd. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.03. The firm had revenue of $85.81 million for the quarter, compared to the consensus estimate of $86.00 million. Xeris Biopharma had a net margin of 0.19% and a negative return on equity of 5.33%. On average, equities analysts anticipate that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on XERS shares. Wall Street Zen raised shares of Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 7th. Barclays initiated coverage on Xeris Biopharma in a research report on Monday, December 8th. They set an “overweight” rating and a $9.00 target price on the stock. Weiss Ratings upgraded Xeris Biopharma from a “sell (d-)” rating to a “hold (c-)” rating in a report on Wednesday, March 4th. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Xeris Biopharma in a research report on Monday, March 2nd. Four analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, Xeris Biopharma currently has a consensus rating of “Moderate Buy” and an average price target of $10.80.

Insider Activity at Xeris Biopharma

In other news, Director John Johnson sold 135,400 shares of the business’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $7.22, for a total transaction of $977,588.00. Following the sale, the director directly owned 698,083 shares of the company’s stock, valued at $5,040,159.26. The trade was a 16.25% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider John Patrick Shannon, Jr. sold 24,907 shares of the company’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $7.08, for a total value of $176,341.56. Following the completion of the transaction, the insider directly owned 2,705,346 shares in the company, valued at approximately $19,153,849.68. The trade was a 0.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 225,308 shares of company stock worth $1,626,103. 6.47% of the stock is owned by company insiders.

Xeris Biopharma Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.